The patient access system wasn't designed for today's rare disease therapies. There's an opportunity to build something better—infrastructure that works for patients, payers, and manufacturers alike.
Our AI aggregates clinical literature, guidelines, and case evidence to build comprehensive documentation for each patient.
Complete, well-organized evidence helps authorization decisions happen faster and with more confidence.
We identify documentation needs, help compile supporting materials, and streamline the submission process.
Time-to-therapy drops from weeks to days. Fewer patients fall through the cracks.
We support long-term patient tracking—aggregating data from multiple sources over months and years.
As outcomes-based payment models expand, this infrastructure becomes essential. We're building it now.
Basion isn't just infrastructure—it's a platform that thousands of rare disease patients use every day.
When a therapy launches, patients aren't starting from scratch. They're prepared, informed, and supported by a platform they already know.
The CMS Cell and Gene Therapy Access Model launched in January 2025, requiring outcomes-based payments for participating therapies. This is just the beginning.
We're building the foundation for how rare disease therapies will be delivered and paid for in the years ahead.
Whether you're preparing for a launch or looking to improve existing patient support, we'd love to learn more about your needs.